Dignitana report
The Dignitana report today made the share fall more than 8 %. To some extent I understand the sellers, but I still find Dignitana a profitable case for a long- and midterm investor - and awaits the FDA-approval of the Dignicap sytem. The report can be found under IR at www.dignitana.se In the light of the China share-unrest, a fall of more than 8 % is understandable, but compared to the mid- and long-term possiblities of Dignitana the fall must be seen as temporaraly. ...